HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung CancerGlobeNewsWire • 09/09/24
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in ChinaGlobeNewsWire • 08/30/24
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review StatusGlobeNewsWire • 07/04/24
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by TakedaGlobeNewsWire • 06/21/24
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet HaematologyGlobeNewsWire • 06/17/24
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in ChinaGlobeNewsWire • 06/07/24
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature MedicineGlobeNewsWire • 06/03/24
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committeesGlobeNewsWire • 05/17/24
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 CongressGlobeNewsWire • 05/17/24
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with HengruiGlobeNewsWire • 05/14/24
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in ChinaGlobeNewsWire • 05/14/24
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board CommitteeGlobeNewsWire • 05/08/24
Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?Zacks Investment Research • 04/30/24
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by TakedaGlobeNewsWire • 04/26/24
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review StatusPRNewsWire • 04/02/24
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review StatusGlobeNewsWire • 04/02/24
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLCGlobeNewsWire • 03/28/24